Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten Sells 40,831 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 40,831 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $35.32, for a total transaction of $1,442,150.92. Following the completion of the transaction, the director now directly owns 193,296 shares of the company’s stock, valued at $6,827,214.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Dirk Kersten also recently made the following trade(s):

• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95.

Dyne Therapeutics Trading Down 3.6 %

Shares of NASDAQ:DYN traded down $1.23 on Tuesday, reaching $33.40. 1,936,244 shares of the company were exchanged, compared to its average volume of 1,608,944. Dyne Therapeutics, Inc. has a 1-year low of $6.40 and a 1-year high of $47.45. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. The company has a 50-day moving average of $40.89 and a 200-day moving average of $33.71.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on DYN shares. JPMorgan Chase & Co. boosted their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Guggenheim boosted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Stifel Nicolaus raised their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.40.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Concurrent Investment Advisors LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $573,000. Sei Investments Co. acquired a new position in Dyne Therapeutics during the 1st quarter valued at $693,000. Rafferty Asset Management LLC grew its holdings in shares of Dyne Therapeutics by 17.7% during the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after purchasing an additional 24,632 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in Dyne Therapeutics in the first quarter valued at about $810,000. Finally, Commodore Capital LP acquired a new position in Dyne Therapeutics during the fourth quarter worth $11,970,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.